Warp Drive Bio, LLC develops genomic technology to discover drugs of natural origin. The company also engages in development of drugs. Warp Drive Bio, LLC was incorporated in 2010 and is based in Cambridge, Massachusetts.
215 First Street
Cambridge, MA 02142
Founded in 2010
Warp Drive Bio, LLC Announces Executive Changes
Jul 2 13
Warp Drive Bio announced the appointment of scientist and company co-founder Gregory Verdine, Ph.D., to chief executive officer. Dr. Verdine succeeds founding CEO Alexis Borisy, who will remain on Warp Drive Bio's board of directors and will assume the position of executive chairman. In addition, Warp Drive Bio has appointed industry veteran James Nichols, Ph.D., to the newly created role of chief operating officer, and drug hunter Julian Adams, Ph.D., to its board of directors. A biopharmaceutical executive and entrepreneur with more than 15 years of life sciences experience, Dr. Nichols joins Warp Drive Bio in the newly created role of chief operating officer. Prior to joining Warp Drive Bio, Dr. Nichols was president and chief operating officer of Resolvyx Pharmaceuticals Inc., where he advanced two programs through early clinical development, led the company's financing and business development activities and closed a strategic partnership on the company's lead clinical ophthalmic program. Prior to joining Resolvyx, Dr. Nichols was vice president of therapeutics at CombinatoRx Inc. (now Zalicus), where he led product and portfolio strategy, overseeing seven programs from discovery through Phase 2, and was instrumental in closing multiple strategic deals and financing rounds. Previously, Dr. Nichols was a management consultant at Braun Consulting, a health care focused consulting firm (acquired by Fair Isaac). He was subsequently a Helen Hay Whitney Postdoctoral at Stanford University Medical School. New board member and world-renowned scientist Dr. Adams currently serves as president, research and development at Infinity Pharmaceuticals Inc., where he is responsible for the full spectrum of Infinity's drug discovery, preclinical and clinical development strategy, and regulatory affairs activities. Prior to joining Infinity in 2003, Dr. Adams was the senior vice president, drug discovery and development at Millennium Pharmaceuticals, where he had global responsibility for multiple drug discovery programs, including the successful discovery and development of Velcade(R) (bortezomib), a proteasome inhibitor for cancer therapy. Earlier in his career, Dr. Adams served in senior positions at LeukoSite and ProScript and as director, medicinal chemistry at Boehringer Ingelheim, where he successfully discovered the drug Viramune(R) (nevirapine) for HIV.